🔴 Crispr Therapeutics is trading 4.45% down on October 6, 2026 as biotech shares weaken

Crispr Therapeutics is trading at $54.79, down 4.45%, amid broader biotech weakness.

• No clear company-specific catalyst for the decline was identified.
• The latest company coverage surfaced a planned November presentation of zugo-cel clinical data, not a new October 6 announcement.
• XBI is down 2.50%, although major U.S. indexes are higher; the available evidence points to sector-wide risk aversion rather than a confirmed company event.